Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nucorion Pharmaceuticals Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is handled by a distinct examiner, which indicates a highly centralized prosecution effort for the company. The presence of a single distinct art unit further suggests that the pending intellectual property is focused within a specific technical niche.
PATRICK T LEWIS is the busiest examiner for this portfolio, currently overseeing the company's active matters. Since the busiest examiner pending count is identical to the total number of actions, this examiner has sole responsibility for the company's active applications. This ratio between the company and the examiner means that the success of the current prosecution cycle depends entirely on the interactions with this specific official. Practitioners should prepare for a focused dialogue, as there are no other active matters to provide broader context within the patent office. The outcome of this 1 pending office action will define the company's immediate success in this sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWIS, PATRICK T | 1 | 74.0% | +14.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18826713 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | LEWIS, PATRICK T | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18826713 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | LEWIS, PATRICK T | 1691 | §112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNucorion Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Patrick T Lewis has the most, with 1 of Nucorion Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
